<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>19535113</identifier>
<setSpec>0025-7753</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Lahoz, Carlos</dc:author>
<dc:author>Mostaza, José M</dc:author>
<dc:description xml:lang="en">The protective role of HDL-cholesterol against atherosclerosis has been established in epidemiological and experimental studies. In spite of this, there are a few of clinical trials that have unequivocally demonstrated that raising HDL-cholesterol reduces the cardiovascular risk. In the present article we review the putative protective mechanisms associated with HDL particles, the evidence linking HDL-cholesterol increase with a reduction in cardiovascular risk as well as the pharmacological and non-pharmacological therapies for increasing HDL-cholesterol. Finally, we comment on experimental drugs currently under development, that elevate HDL-cholesterol.</dc:description>
<dc:type>English Abstract</dc:type>
<dc:language>es</dc:language>
<dc:date>2009 Jul 11 </dc:date>
<dc:title xml:lang="es">Colesterol ligado a lipoproteínas de alta densidad: de factor de riesgo a diana terapéutica.</dc:title>
<dc:title xml:lang="en">[HDL-cholesterol: from risk factor to therapeutic target].</dc:title>
<dc:publisher>Medicina clinica</dc:publisher>
</metadata>
</record>
</pubmed-document>
